|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01276 HENGRUI PHARMA
Nominal 
66.000 +4.750 (+7.755%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 31,629,416 | 13.024% | 27,984,605 | 22,819,785 | 21,275,271 |
| Cost of Sales | (4,362,656) | 13.369% | (3,848,177) | (3,525,248) | (3,486,639) |
| Gross Profit | 27,266,760 | 12.969% | 24,136,428 | 19,294,537 | 17,788,632 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (97,143) | 350.132% | (21,581) | (72,696) | (62,996) | |
| Profit / (Loss) before Taxation | 8,707,625 | 21.451% | 7,169,690 | 4,667,110 | 3,968,492 | |
| Taxation | (990,623) | 18.966% | (832,695) | (389,289) | (153,351) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (5,947) | 1170.726% | (468) | 24,615 | 91,233 | |
| Others | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 7,711,055 | 21.692% | 6,336,527 | 4,302,436 | 3,906,374 | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (771,038) | 28.997% | (597,718) | (471,238) | (378,784) |
| Depreciation & Amortisation | 942,470 | 8.228% | 870,819 | 793,937 | 640,511 |
| Directors' Emoluments | 37,824 | 45.785% | 25,945 | 20,418 | 10,537 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 119.000 | 19.000% | 100.000 | 68.000 | 61.000 |
| DPS (cts) | 20.000 | -- | -- | -- | -- |
| Dividend Payout Ratio (%) | 16.807% | -- | -- | -- | -- |
| Cash flow per share ($) | 1.728 | -- | 1.169 | 1.202 | 0.198 |
| NBV per share ($) | 9.237 | -- | -- | -- | -- |
| Remarks: | Real time quote last updated: 27/03/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 7,711,055 |
| %Change | 21.692% |
| EPS / (LPS) | RMB 1.190 |
| NBV Per Share (¥) | RMB 9.237 |